Tirzepatide for MASH with Liver Fibrosis | NEJM

Name: Tirzepatide for MASH with Liver Fibrosis | NEJM
Uploaded: 2024-07-25T00:00:00
Description: Tirzepatide trial shows 44-62% MASH resolution without fibrosis worsening vs. 10% placebo. Covers 5-15mg weekly dosing and safety profile.

1 min read

Medical Disclaimer: This content is for educational purposes only and is not medical advice. Consult a qualified professional for medical decisions.